Figure 1. Expression of miR-106a-5p in TNBC tissue and cells. (A) MiRNAs expression profiles in normal tissues and cancer tissues of TNBC. (B) The expression of miR-106a-5p in clinical TNBC tissues (n = 20) and adjacent normal tissues (n = 20) determined by qRT-PCR (*p<0.05). (C) qRT-PCR assay analyzed the expression of miR-106a-5p in normal breast cell MCF10A and TNBC cell lines BT549 and MDA-MB-231 (*p<0.05 vs MCF10A). (D) The overall survival of TNBC patients with low (n = 10) or high (n = 9) expression of miR-106a-5p were assessed by Kaplan-Meier survival analysis (*p<0.05). (E) The expression of miR-106a-5p in TNBC tissues from patients with tumor grade 0 to grade IV (n = 6) was measured by qRT-PCR (*p<0.05 vs grade 0). The above measurement data were expressed as mean ± standard deviation. Data among multiple groups were analyzed by one-way ANOVA, followed by a Tukey post hoc test. The experiment was repeated in triplicate.